Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials

BACKGROUND: For patients with metastatic renal cell carcinoma (mRCC) who progress on standard-of-care therapies, there is an unmet need for novel treatments. Phase I clinical trials are designed to test the safety, toxicity and optimal dosing of novel agents. Herein, we analysed the outcomes of pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Hahn, Andrew W, Alhalabi, Omar, Msaouel, Pavlos, Meric-Bernstam, Funda, Naing, Aung, Jonasch, Eric, Piha-Paul, Sarina, Hong, David, Pant, Shubham, Yap, Timothy, Campbell, Erick, Le, Hung, Tannir, Nizar M., Roszik, Jason, Subbiah, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684827/
https://www.ncbi.nlm.nih.gov/pubmed/33229506
http://dx.doi.org/10.1136/esmoopen-2020-001073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684827/
https://www.ncbi.nlm.nih.gov/pubmed/33229506
http://dx.doi.org/10.1136/esmoopen-2020-001073

Ejemplares similares